Corton Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Corton Capital’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-22,074	Closed	-$104K	–	662
2024 Q3	$104K	Buy	+22,074	New	+$118K	0.05%	449

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Corton Capital's VNDA Position: Q4 2024 in Review

Corton Capital sold out of Vanda Pharmaceuticals (VNDA) in Q4 2024, closing a stake of 22,074 shares — an estimated $104K sold.

Corton Capital first reported a position in VNDA in Q3 2024 and held it in 1 quarter. The position peaked at $104K in Q3 2024. 146 funds tracked by Wall St. Rank hold VNDA as of Q4 2024.

Corton Capital reported no remaining Vanda Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Corton Capital sold 22,074 Vanda Pharmaceuticals shares in Q4 2024, an estimated $104K.
Corton Capital first reported a position in Vanda Pharmaceuticals in Q3 2024 and held it in 1 quarter.
Corton Capital's Vanda Pharmaceuticals position peaked at $104K in Q3 2024.
146 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2024.

Based on Corton Capital's 13F filing for Q4 2024, filed 14 Feb 2025.